Veru (VERU) Cash & Current Investments (2010 - 2026)
Veru (VERU) posted quarterly Cash & Current Investments of $30.8 million for Q1 2026, up 53.68% year-over-year from $20.0 million in Q1 2025, and down 13.09% quarter-over-quarter from $35.4 million in Q4 2025.
Veru (VERU) Cash & Current Investments (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Cash & Current Investments for 17 consecutive years, with $30.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 53.68% year-over-year to $30.8 million; the TTM figure through Mar 2026 stood at $30.8 million (up 53.68% YoY), while the FY2025 annual figure was $18.3 million, down 28.6% from the prior year.
- Cash & Current Investments fell to $30.8 million in Q1 2026 per VERU's latest filing, from $35.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $112.0 million in Q1 2022 and bottomed at $9.6 million in Q3 2023.
- Historically, Cash & Current Investments has averaged $39.1 million across 5 years, with a median of $29.2 million in 2024.
- Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 88.0% — and 2024, when it soared 166.57%.
- Veru's Cash & Current Investments stood at $46.9 million in 2022, then declined by 13.53% to $40.6 million in 2023, then slumped by 34.43% to $26.6 million in 2024, then surged by 33.04% to $35.4 million in 2025, then fell by 13.09% to $30.8 million in 2026.
- Business Quant data shows VERU's Cash & Current Investments at $30.8 million in Q1 2026, $35.4 million in Q4 2025, and $18.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 25.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.79 Mn |
| Mar 31, 2026 | 30.76 Mn |
| Dec 31, 2025 | 35.40 Mn |
| Sep 30, 2025 | 18.32 Mn |
| Jun 30, 2025 | 15.01 Mn |
| Mar 31, 2025 | 20.02 Mn |
| Dec 31, 2024 | 26.61 Mn |
| Sep 30, 2024 | 25.66 Mn |
| Jun 30, 2024 | 29.15 Mn |
| Mar 31, 2024 | 34.74 Mn |
| Dec 31, 2023 | 40.58 Mn |
| Sep 30, 2023 | 9.63 Mn |
| Jun 30, 2023 | 16.21 Mn |
| Mar 31, 2023 | 23.50 Mn |
| Dec 31, 2022 | 46.93 Mn |
| Sep 30, 2022 | 80.19 Mn |
| Jun 30, 2022 | 100.55 Mn |
| Mar 31, 2022 | 112.02 Mn |
| Dec 31, 2021 | 116.10 Mn |
| Sep 30, 2021 | 122.36 Mn |